logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Gonadotropin Releasing Hormone Receptor Agonist class drugs

    FiltersReset Filters
    13 results

    • eligard

      (Leuprolide Acetate)
      TOLMAR Inc.
      Usage: ELIGARD® is indicated for the palliative treatment of advanced prostate cancer.

    • fensolvi

      (Leuprolide Acetate)
      TOLMAR Inc.
      Usage: FENSOLVI® is indicated for treating central precocious puberty (CPP) in pediatric patients aged 2 years and older.

    • leuprolide acetate

      (leuprolide acetate)
      UBI Pharma Inc.
      Usage: Leuprolide acetate injection is indicated for the palliative treatment of advanced prostatic cancer.

    • leuprolide acetate

      (Leuprolide Acetate)
      VGYAAN Pharmaceuticals LLC
      Usage: Leuprolide acetate injection is indicated for the palliative treatment of advanced prostatic cancer.

    • leuprolide acetate

      (Leuprolide Acetate)
      Sandoz Inc
      Usage: Leuprolide acetate injection is indicated for the palliative treatment of advanced prostatic cancer.

    • leuprolide acetate

      (leuprolide acetate)
      Amneal Pharmaceuticals LLC
      Usage: Leuprolide acetate injection is indicated for the palliative treatment of advanced prostatic cancer.

    • leuprolide acetate

      (Leuprolide Acetate)
      NorthStar RxLLC
      Usage: Leuprolide acetate injection is indicated for the palliative treatment of advanced prostatic cancer.

    • lupron depot

      (leuprolide acetate)
      AbbVie Inc.
      Usage: LUPRON DEPOT 11.25 mg is indicated for managing endometriosis, including pain relief and lesion reduction, as well as for preoperative anemia improvement in women with uterine leiomyomata (fibroids), used with iron therapy. It is not meant for prolonged use or specific combinations beyond stated limits.

    • lupron depot-ped

      (leuprolide acetate)
      AbbVie Inc.
      Usage: LUPRON DEPOT-PED is indicated for treating pediatric patients with central precocious puberty (CPP).

    • supprelin

      (histrelin acetate)
      ENDO USA, Inc.
      Usage: SUPPRELIN LA (histrelin acetate) is indicated for treating children with central precocious puberty (CPP), characterized by early sexual development before age 8 in females and 9 in males, and advanced bone age. Diagnosis should be confirmed through hormonal assessments and imaging to rule out underlying conditions.